Vanda Pharmaceuticals Urges FDA to Accelerate Shift Toward Human-Relevant Testing Methods

Vanda Pharmaceuticals has called on the U.S. Food and Drug Administration (FDA) to take stronger regulatory action to accelerate the transition from animal testing to human-relevant research methods, emphasizing the need for modern scientific approaches that improve drug development efficiency, safety, and ethical standards.

Advocating for Modernized Drug Testing Frameworks

The company highlighted growing advancements in alternative testing technologies, such as organ-on-chip systems and computational models, which can better predict human responses compared to traditional animal studies. Vanda stressed that regulatory support is essential to validate and integrate these methods into mainstream drug approval processes.

Implications for Pharma Innovation and Ethics

This push reflects a broader industry shift toward more sustainable and patient-relevant research practices. Accelerating the adoption of non-animal testing methods could reduce development timelines, lower costs, and address ethical concerns, while positioning regulatory bodies like the FDA as key enablers of next-generation biomedical innovation.